RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Rating of “Hold” by Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been assigned an average recommendation of “Hold” from the thirteen brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $9.56.

A number of equities research analysts have recently issued reports on the stock. Piper Sandler cut shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $8.00 to $2.00 in a research report on Monday, November 11th. HC Wainwright raised shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Thursday, December 26th. Stifel Nicolaus reaffirmed a “hold” rating and set a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Finally, Wells Fargo & Company lowered their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 12th.

Institutional Trading of RAPT Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Readystate Asset Management LP bought a new position in RAPT Therapeutics in the third quarter valued at about $36,000. Bank of New York Mellon Corp boosted its stake in shares of RAPT Therapeutics by 24.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock valued at $349,000 after purchasing an additional 22,175 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares during the last quarter. Barclays PLC increased its position in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after purchasing an additional 29,195 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in RAPT Therapeutics by 66.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock valued at $258,000 after purchasing an additional 33,692 shares during the last quarter. 99.09% of the stock is currently owned by institutional investors.

RAPT Therapeutics Stock Down 9.4 %

RAPT Therapeutics stock opened at $1.45 on Friday. RAPT Therapeutics has a twelve month low of $0.79 and a twelve month high of $27.35. The stock has a market cap of $50.69 million, a P/E ratio of -0.52 and a beta of 0.07. The company’s 50-day moving average price is $1.46 and its two-hundred day moving average price is $2.07.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.09. Equities analysts anticipate that RAPT Therapeutics will post -2.86 earnings per share for the current fiscal year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.